Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Raymond Wong, Sergio A. Giralt, Thomas Martin, Daniel R. Couriel, Athanasios Anagnostopoulos, Chitra Hosing, Borje S. Andersson, Pedro Cano, Munir Shahjahan, Cindy Ippoliti, Elihu H. Estey, John McMannis, James L. Gajewski, Richard E. Champlin, Marcos De Lima

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Hematopoietic stem cell transplantation from unrelated donors is an effective treatment for myeloid malignancies, but its use is usually restricted to young patients without comorbidities. The development of reduced-intensity preparative regimens has allowed the extension of this form of treatment to older and medically infirm patients. We assessed the outcomes of patients older than 54 years who received unrelated donor transplants for the treatment of myeloid malignancies in our institution. There were 29 patients (median age, 59 years) with advanced acute myeloid leukemia (n = 13), myelodysplastic syndrome (n = 7), and chronic myeloid leukemia (n = 9) included. With a median follow-up of 27 months, the probability of overall and event-free survival, and nonrelapse mortality at one year were 44%, 37%, and 55%, respectively. Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41% of patients and chronic GVHD developed in 63% of patients surviving more than 100 days. Of the 11 survivors, 9 were interviewed and reported good quality of life after transplantation using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, with high scores in all dimensions. Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease.

Original languageEnglish (US)
Pages (from-to)3052-3059
Number of pages8
JournalBlood
Volume102
Issue number8
DOIs
StatePublished - Oct 15 2003
Externally publishedYes

Fingerprint

Unrelated Donors
Hematopoietic Stem Cell Transplantation
Stem cells
Transplants
Grafts
Functional assessment
Neoplasms
Bone
Therapeutics
Graft vs Host Disease
Transplantation
Bone Neoplasms
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Disease-Free Survival
Survivors
Comorbidity
Bone Marrow
Quality of Life

ASJC Scopus subject areas

  • Hematology

Cite this

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. / Wong, Raymond; Giralt, Sergio A.; Martin, Thomas; Couriel, Daniel R.; Anagnostopoulos, Athanasios; Hosing, Chitra; Andersson, Borje S.; Cano, Pedro; Shahjahan, Munir; Ippoliti, Cindy; Estey, Elihu H.; McMannis, John; Gajewski, James L.; Champlin, Richard E.; De Lima, Marcos.

In: Blood, Vol. 102, No. 8, 15.10.2003, p. 3052-3059.

Research output: Contribution to journalArticle

Wong, R, Giralt, SA, Martin, T, Couriel, DR, Anagnostopoulos, A, Hosing, C, Andersson, BS, Cano, P, Shahjahan, M, Ippoliti, C, Estey, EH, McMannis, J, Gajewski, JL, Champlin, RE & De Lima, M 2003, 'Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years', Blood, vol. 102, no. 8, pp. 3052-3059. https://doi.org/10.1182/blood-2003-03-0855
Wong, Raymond ; Giralt, Sergio A. ; Martin, Thomas ; Couriel, Daniel R. ; Anagnostopoulos, Athanasios ; Hosing, Chitra ; Andersson, Borje S. ; Cano, Pedro ; Shahjahan, Munir ; Ippoliti, Cindy ; Estey, Elihu H. ; McMannis, John ; Gajewski, James L. ; Champlin, Richard E. ; De Lima, Marcos. / Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. In: Blood. 2003 ; Vol. 102, No. 8. pp. 3052-3059.
@article{9d4ecccb36454c10bed366b1940ff6f8,
title = "Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years",
abstract = "Hematopoietic stem cell transplantation from unrelated donors is an effective treatment for myeloid malignancies, but its use is usually restricted to young patients without comorbidities. The development of reduced-intensity preparative regimens has allowed the extension of this form of treatment to older and medically infirm patients. We assessed the outcomes of patients older than 54 years who received unrelated donor transplants for the treatment of myeloid malignancies in our institution. There were 29 patients (median age, 59 years) with advanced acute myeloid leukemia (n = 13), myelodysplastic syndrome (n = 7), and chronic myeloid leukemia (n = 9) included. With a median follow-up of 27 months, the probability of overall and event-free survival, and nonrelapse mortality at one year were 44{\%}, 37{\%}, and 55{\%}, respectively. Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41{\%} of patients and chronic GVHD developed in 63{\%} of patients surviving more than 100 days. Of the 11 survivors, 9 were interviewed and reported good quality of life after transplantation using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, with high scores in all dimensions. Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease.",
author = "Raymond Wong and Giralt, {Sergio A.} and Thomas Martin and Couriel, {Daniel R.} and Athanasios Anagnostopoulos and Chitra Hosing and Andersson, {Borje S.} and Pedro Cano and Munir Shahjahan and Cindy Ippoliti and Estey, {Elihu H.} and John McMannis and Gajewski, {James L.} and Champlin, {Richard E.} and {De Lima}, Marcos",
year = "2003",
month = "10",
day = "15",
doi = "10.1182/blood-2003-03-0855",
language = "English (US)",
volume = "102",
pages = "3052--3059",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

AU - Wong, Raymond

AU - Giralt, Sergio A.

AU - Martin, Thomas

AU - Couriel, Daniel R.

AU - Anagnostopoulos, Athanasios

AU - Hosing, Chitra

AU - Andersson, Borje S.

AU - Cano, Pedro

AU - Shahjahan, Munir

AU - Ippoliti, Cindy

AU - Estey, Elihu H.

AU - McMannis, John

AU - Gajewski, James L.

AU - Champlin, Richard E.

AU - De Lima, Marcos

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Hematopoietic stem cell transplantation from unrelated donors is an effective treatment for myeloid malignancies, but its use is usually restricted to young patients without comorbidities. The development of reduced-intensity preparative regimens has allowed the extension of this form of treatment to older and medically infirm patients. We assessed the outcomes of patients older than 54 years who received unrelated donor transplants for the treatment of myeloid malignancies in our institution. There were 29 patients (median age, 59 years) with advanced acute myeloid leukemia (n = 13), myelodysplastic syndrome (n = 7), and chronic myeloid leukemia (n = 9) included. With a median follow-up of 27 months, the probability of overall and event-free survival, and nonrelapse mortality at one year were 44%, 37%, and 55%, respectively. Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41% of patients and chronic GVHD developed in 63% of patients surviving more than 100 days. Of the 11 survivors, 9 were interviewed and reported good quality of life after transplantation using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, with high scores in all dimensions. Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease.

AB - Hematopoietic stem cell transplantation from unrelated donors is an effective treatment for myeloid malignancies, but its use is usually restricted to young patients without comorbidities. The development of reduced-intensity preparative regimens has allowed the extension of this form of treatment to older and medically infirm patients. We assessed the outcomes of patients older than 54 years who received unrelated donor transplants for the treatment of myeloid malignancies in our institution. There were 29 patients (median age, 59 years) with advanced acute myeloid leukemia (n = 13), myelodysplastic syndrome (n = 7), and chronic myeloid leukemia (n = 9) included. With a median follow-up of 27 months, the probability of overall and event-free survival, and nonrelapse mortality at one year were 44%, 37%, and 55%, respectively. Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41% of patients and chronic GVHD developed in 63% of patients surviving more than 100 days. Of the 11 survivors, 9 were interviewed and reported good quality of life after transplantation using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, with high scores in all dimensions. Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0141958295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141958295&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-03-0855

DO - 10.1182/blood-2003-03-0855

M3 - Article

VL - 102

SP - 3052

EP - 3059

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -